Document:

Exhibit

Exhibit 10.1
[Letterhead of the U.S. Department of the Treasury]

Secretary of the Treasury

December 21, 2017

The Honorable Melvin L. Watt
Director
Federal Housing Finance Agency
400 7th Street, SW
Washington, DC  20219

Dear Director Watt:

Reference is made to the Amended and Restated Preferred Stock Purchase Agreement dated as of September 26, 2008, as amended (the Agreement), between the United States Department of the Treasury (Treasury) and the Federal National Mortgage Association (the Enterprise), acting through the Federal Housing Finance Agency as its Conservator, and the Amended and Restated Certificate of Designation (the Certificate) executed pursuant to the Agreement.  Capitalized terms used herein without definition have the meanings assigned to them in the Agreement and the Certificate.

In the Agreement, Treasury committed itself to provide to the Enterprise, on the terms and conditions provided in the Agreement, immediately available funds in an amount determined from time to time as provided in the Agreement, but in no event in an aggregate amount exceeding $100,000,000,000.  In consideration for Treasury’s commitment, the Enterprise agreed to sell, and did sell, to Treasury 1,000,000 shares of senior preferred stock, in the form of Variable Liquidation Preference Senior Preferred Stock of the Enterprise with terms set forth in the Certificate, and an initial liquidation preference equal to $1,000 per share.

The Agreement provides that the aggregate liquidation preference of the outstanding shares of senior preferred stock shall be automatically increased by an amount equal to the amount of each draw under Treasury’s funding commitment, and the Certificate originally provided that the senior preferred stock shall accrue dividends at the annual rate per share equal to 10 percent on the then-current liquidation preference.

Treasury and the Enterprise have heretofore entered into:

(a) the Amendment dated as of May 6, 2009, to the Agreement, in which Treasury increased to $200,000,000,000 the maximum aggregate amount permitted to be provided to the Enterprise under the Agreement, and amended the terms of the Agreement in certain other respects;

(b) the Second Amendment dated as of December 24, 2009, to the Agreement, in which Treasury modified the maximum aggregate amount permitted to be provided to the Enterprise under the Agreement, as previously amended, by replacing the fixed maximum aggregate 

amount with the new formulaic maximum amount specified therein, and amended the terms of the Agreement, as previously amended, in certain other respects; and,

(c) the Third Amendment dated as of August 17, 2012, to the Agreement, in which the Enterprise modified the dividend rate provision set forth in the Certificate, and amended the terms of the Agreement, as previously amended, in certain other respects.

Treasury and the Enterprise are each authorized to enter into this letter agreement further amending the Certificate by modifying the dividend and liquidation preference provisions of the senior preferred stock sold by the Enterprise to Treasury.  Therefore, for and in consideration of the mutual agreements herein contained and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Treasury and the Enterprise agree as follows:

Fourth Quarter Dividend

Section 2(a) of the Certificate provides that Treasury, as the holder of outstanding shares of Senior Preferred Stock of the Enterprise, shall be entitled to receive, when, as, and if declared by the Board of Directors, in its sole discretion, cumulative cash dividends quarterly on each Dividend Payment Date.  The Enterprise agrees to declare and pay the dividend payable to Treasury for the Dividend Period that ends on December 31, 2017 in an amount equal to the Dividend Amount minus $2,400,000,000 (the Q4 Dividend).

Applicable Capital Reserve Amount

Section 10(g)(ii) of the Certificate provides that the consent of Treasury, as the holder of at least two-thirds of the outstanding shares of Senior Preferred Stock, is necessary to authorize any amendment of the Certificate affecting the interests of the holders.  Effective upon receipt of the Q4 Dividend, Treasury agrees that the Enterprise will either amend the Certificate, or issue a replacement Certificate, in either case so that, effective January 1, 2018, paragraph 2(c) reads as follows: 

(c) For each Dividend Period from the date of the initial issuance of the Senior Preferred Stock through and including December 31, 2012, “Dividend Rate” means 10.0 percent; provided, however, that if at any time the Company shall have for any reason failed to pay dividends in cash in a timely manner as required by this Certificate, then immediately following such failure and for all Dividend Periods thereafter until the Dividend Period following the date on which the Company shall have paid in cash full cumulative dividends (including any unpaid dividends added to the Liquidation Preference pursuant to Section 8) the “Dividend Rate” shall mean 12.0 percent. 

For each Dividend Period from January 1, 2013, and thereafter, the “Dividend Amount” for a Dividend Period means the amount, if any, by which the Net Worth Amount at the end of the immediately preceding fiscal quarter, less the Applicable Capital Reserve Amount for such Dividend Period, exceeds zero.  In each case, “Net Worth Amount” means (i) the total assets of the Company (such assets excluding the Commitment and any unfunded amounts thereof) as reflected on the balance sheet of the Company as of the applicable date set forth in this Certificate, prepared in accordance with GAAP, less (ii) the total liabilities of the Company (such liabilities excluding any obligation in respect of any capital stock of the 

2

Company, including this Certificate), as reflected on the balance sheet of the Company as of the applicable date set forth in this Certificate, prepared in accordance with GAAP.  “Applicable Capital Reserve Amount” means, as of any date of determination, (A) for each Dividend Period from January 1, 2013, through and including December 31, 2013, $3,000,000,000; (B) for each Dividend Period occurring within each 12-month period thereafter, through and including December 31, 2017, $3,000,000,000 reduced by $600,000,000 for each such 12-month period, so that for each Dividend Period from January 1, 2017, through and including December 31, 2017, the Applicable Capital Reserve Amount shall be $600,000,000; and (C) for each Dividend Period from January 1, 2018, and thereafter, $3,000,000,000.  Notwithstanding the foregoing, for each Dividend Period from January 1, 2018, and thereafter, following any Dividend Payment Date with respect to which the Board of Directors does not declare and pay a dividend or declares and pays a dividend in an amount less than the Dividend Amount, the Applicable Capital Reserve Amount shall thereafter be zero.  For the avoidance of doubt, if the calculation of the Dividend Amount for a Dividend Period does not exceed zero, then no Dividend Amount shall accrue or be payable for such Dividend Period.

For the avoidance of doubt, following the amendment of the Certificate as provided in this Letter Agreement, Section 2 of the Certificate, as amended hereby, shall be deemed to be in form and content substantially the same as the form and content of the Senior Preferred Stock in effect on September 30, 2012.

Increase in Liquidation Preference 

The Enterprise and Treasury agree that, notwithstanding Sections 2(b) and 8(b)(iii) of the Certificate, the Liquidation Preference shall be increased by $3,000,000,000 on December 31, 2017.

Sincerely,

/s/ Steven T. Mnuchin

Steven T. Mnuchin

Agreed and Accepted:

Federal National Mortgage Association, by
Federal Housing Finance Agency, its Conservator

     /s/ Melvin L. Watt    
Melvin L. Watt
Director

3EX-10.1

 Exhibit 10.1 
  

 
 Confidential 

December 18, 2017 
 Bryan Hanson 

Dear Bryan: 
 We are pleased to offer you the role of President
and Chief Executive Officer (CEO) of Zimmer Biomet Holdings, Inc. (the Company or Zimmer Biomet). You will report directly to the Company’s Board of Directors and lead the Zimmer Biomet Operating Committee. 

In this role, your initial annualized salary will be one million fifty thousand dollars ($1,050,000) payable in biweekly installments of forty thousand three
hundred eighty-four dollars and sixty-two cents ($40,384.62). Your salary grade will be level Z01. Your start date will be Tuesday, December 19, 2017. 

Annual Merit Adjustment 
 Zimmer Biomet’s
annual merit review process involves base pay adjustments consistent with job performance. Merit adjustments are based on performance during the calendar year. You will be eligible for a merit increase beginning in 2019. 

Executive Performance Incentive Plan 
 You will be
eligible to participate in the 2018 Executive Performance Incentive Plan (EPIP). Performance period is from January 1 to December 31, 2018. Your target bonus will be one hundred thirty percent (130%) of your annual base salary (eligible
earnings). Payout may be more or less than this target percentage, depending on actual year-end results for the established performance measures. Payment will occur in or around March of the year following the
bonus period after annual performance measures upon which the bonus is based have been determined. You must remain employed by Zimmer Biomet at the time of bonus payout to receive the bonus. 

2018 Long-Term Incentive (LTI) Plan Award 
 Zimmer
Biomet annual LTI Plan grants have two components: 
  

	 	•	 	Stock options; and 

  

	 	•	 	Performance-based Restricted Stock Units. 

 The LTI structure currently offers participants a diversified award
of 50% stock options and 50% performance-based restricted stock units (PRSUs) that can provide more consistent value than an award of stock options alone. Further, we believe this structure assists the Company in remaining competitive within the
global labor market and creates a compelling and valuable long-term incentive for participants. We will review the performance metrics, equity award types and value mix in conjunction with the 2018 annual grant, along with your input and approval by
the Compensation and Management Development Committee of the Board of Directors (Compensation Committee). Thereafter, applicable performance metrics, equity award types and value mix will be subject to annual review and approval by the Compensation
Committee. 
  

			
	

	 	Page 1

 

 
  

 For 2018, your estimated LTI Plan grant date fair value is approximately seven million one hundred thousand
dollars ($7,100,000). We anticipate the grant date (subject to Compensation Committee approval) of the 2018 award will be in March 2018. 
 LTI grant values
are based upon our compensation philosophy, which is reviewed annually by the Compensation Committee and adjusted as warranted. Please keep in mind that your job responsibilities, performance against your goals and objectives, the overall financial
results of the Company and peer group / market compensation practices also impact LTI grant values each year. 
 All awards are subject to Compensation
Committee approval and other terms and conditions of the 2009 Stock Incentive Plan, as amended from time to time, award agreements, and your execution of a non-disclosure, intellectual property and restrictive
covenant agreement in the form provided by the Company. 
 Former Employer Prorated Bonus Forfeiture Replacement 

Subject to your providing documentation evidencing your forfeiture of bonus eligibility with your former employer as a result of your leaving that employment
to serve as President and CEO of Zimmer Biomet, the Company will pay you a cash bonus of $573,000 to approximate your prorated bonus from your former employer. The amount of forfeiture is calculated assuming one hundred percent (100%) achievement of
measures upon which the bonus amount is determined, and assuming payout for a prorated period of time beginning May 1, 2017 and ending December 31, 2017. 

Zimmer Biomet will issue this payment to you within ninety (90) calendar days of the later of your Zimmer Biomet hire date or the date that your bonus
ineligibility is confirmed by your former employer. Payment will be made less applicable tax withholdings and will not be treated as compensation for purpose of any other bonus or benefit plan. As a condition of payment you must agree by your
signature below that in the event of your voluntary separation from Zimmer Biomet employment before the first anniversary of your date of hire, you will repay, on or before your last day of employment, the full gross amount of this Bonus Forfeiture
Replacement. 
 One-Time Sign-on Equity Award 

As an incentive for you to serve as the Company’s President and CEO, as soon as administratively feasible following your commencement of employment with
the Company but subject to cancellation as described below, the Company will issue to you: 
  

	 	a)	Stock options with a grant date fair value of approximately three million five hundred fifty thousand dollars ($3,550,000) vesting twenty-five percent (25%) per year over a four-
(4-) year period subject to continued employment on each vesting date, with such vesting on the anniversary dates of the grant, and with a term of ten (10) years; and 

 

	 	b)	 PRSUs with performance measured by the Company’s achievement of absolute stock price hurdles (Stock Price
PRSUs) with a grant date fair value of approximately three million five hundred fifty thousand dollars ($3,550,000) vesting on the fourth (4th) anniversary of the grant subject to continued employment on such date and achievement of the specified
performance goals and other conditions as provided in 

  

			
	

	  	Page 2

 

 
  

	 	
the award agreement. One-third (1/3) of the Stock Price PRSUs will become eligible to vest if the Company’s closing stock price achieves each of three
(3) hurdles for twenty (20) consecutive trading days, with hurdles set at twenty percent (20%), thirty-five percent (35%) and fifty percent (50%) growth over the average closing stock price for the thirty (30) trading days immediately
prior to the grant date. 

 This one-time sign-on equity award
is subject to cancellation unless you execute, during periods of open trading in accordance with applicable law and the Company’s policies and procedures, an open-market purchase of at least $3,000,000 of Zimmer Biomet common stock within your
first 90 business days of employment. Please note, the Company anticipates that the open trading window during your first 90 business days of employment will run from approximately January 29, 2018 through March 14, 2018, taking into
consideration the Q4 2017 and Q1 2018 quarterly blackout periods under the Company’s Stock Trading Policy. 
 Replacement Equity Award for
Forfeited Equity Awards 
 As a further incentive for you to serve as Zimmer Biomet’s President and CEO, and recognizing that in doing so you
will forfeit certain equity compensation opportunities with your previous employer, Zimmer Biomet will, upon or as soon as administratively feasible following your commencement of employment, issue to you equity awards with an aggregate grant date
fair value of approximately $8,589,000 as a one-time replacement of forfeited equity awards at your former employer. These equity awards will consist of: 

 

	 	a)	Stock options with a grant date fair value of approximately two million seven hundred fifty thousand dollars ($2,750,000) vesting twenty-five percent (25%) per year over a four- (4-) year period subject to your
continued employment on each vesting date, with such vesting on the anniversary dates of the grant, and with a term of ten (10) years and an exercise price equal to the fair market value of Zimmer Biomet common stock on the grant date;

  

	 	b)	Time-Based Restricted Stock Units (RSUs) with a grant date fair value of approximately three million eighty-nine thousand dollars ($3,089,000) vesting thirty-three and one-third
percent (33-1/3%) per year over a three-year period subject to your continued employment on each vesting date; and 

  

	 	c)	Stock Price PRSUs with a grant date fair value of approximately two million seven hundred fifty thousand dollars ($2,750,000) vesting on the fourth (4th) anniversary of the grant subject to your continued employment on
the vesting date and achievement of the specified performance goals and other conditions as provided in the award agreement. One-third (1/3) of the Stock Price PRSUs will become eligible to vest if, during the
four- (4-) year performance period, the Company’s closing stock price achieves each of three (3) hurdles for twenty (20) consecutive trading days, with hurdles set at twenty percent (20%),
thirty-five percent (35%) and fifty percent (50%) growth over the average closing stock price for the thirty (30) trading days immediately prior to the grant date. 

Executive Officer (Section 16) 
 You will be
designated by the Board of Directors as an “officer” of Zimmer Biomet for purposes of Rule 16a-1(f) and as an “executive officer” for purposes of Rule
3b-7 under the Securities Exchange Act of 1934, as amended. 

  

			
	

	  	Page 3

 

 
  

 As an executive officer, you will be subject to stock ownership guidelines established by the Board of
Directors in order to align the interests of executive officers more closely with those of stockholders. The guidelines will require you to own shares with a value equal to at least six (6) times your base salary. Under the guidelines, all
shares you hold, including all RSUs and PRSUs you hold (at the target award level), will count toward this ownership requirement. In addition, one-half (1/2) of any gain on vested stock options will count
toward this requirement. You will have up to five (5) years to achieve the required level of stock ownership. Further, every executive officer must obtain clearance prior to selling any shares of Company common stock, in part to ensure that all
officers remain in compliance with the stock ownership guidelines. These stock ownership guidelines are reviewed and subject to modification by the Board of Directors from time to time. 

Change In Control Severance Agreement 
 In your
role, you will be offered a Change In Control Severance Agreement (CIC Agreement), subject to your entering into the enclosed non-disclosure, intellectual property and restrictive covenant agreement. The CIC
Agreement would provide you an offer of certain severance benefits should there be a change in control (CIC) of Zimmer Biomet and resulting, qualifying termination of your employment within the specified time period. 

Briefly, the CIC Agreement terms include: 
  

	 	•	 	Double Trigger – a severance benefit offer would be triggered by a CIC of the Company and your termination of employment by the Company without Cause or by you for Good Reason, as those terms are defined in
the Agreement. 

  

	 	•	 	Window – two (2) years post-CIC. 

  

	 	•	 	Severance Benefits – 

  

	 	•	 	Three times (3x) the sum of base salary plus target bonus, plus a pro rata portion of all contingent incentive programs at target levels, all paid in lump-sum form less applicable
tax withholdings. In the event of a qualifying termination of employment following a Potential Change in Control, incentive program severance amounts are computed by reference to historical, rather than target, amounts. 

 

	 	•	 	Excise Tax Adjustment – In the event payments would trigger excise tax under IRS rules and regulations, the amount of severance will be reduced to a level that does not trigger the tax. 

 

	 	•	 	Equity – To the extent not otherwise provided under the written agreement evidencing the grant: 

  

	 	•	 	All outstanding stock options held will fully vest and be exercisable. 

  

	 	•	 	All time-based restrictions imposed under all outstanding awards of restricted stock and restricted stock units will immediately lapse. 

 

	 	•	 	With respect to performance-based awards, the number of shares or units deemed earned will be the greater of (i) the target number or (ii) the number that would have been earned based on actual
performance from the beginning of the award period to the date of the CIC. 

  

	 	•	 	Health Insurance Benefit – A lump sum payment equal to the cost of twenty-four (24) months of COBRA coverage (medical and dental) at the rate in effect at your separation date for the level of coverage
you have in place at that time. 

  

	 	•	 	Outplacement – Six (6) months of outplacement and support services. 

  

			
	

	  	Page 4

 

 
  

	 	•	 	Life Insurance Benefit – Continuation for a two- (2-) year period after your date of termination of employment, reduced to the
extent you obtain comparable coverage at no greater cost to you, or two (2) years’ worth of the premium cost in lieu of such coverage. 

  

	 	•	 	Tax Liability – Any and all severance payments and benefits will be reported as taxable income and subject to applicable withholdings in accordance with IRS rules and regulations in effect at the
time. 

  

	 	•	 	General Release Requirement – All severance benefits provided under the CIC Agreement are subject to and contingent upon your entering into a general release in a form specified by the CIC Agreement.

 This summary is for informational purposes; in the event of any ambiguity or conflict with the terms of the CIC Agreement, the terms of the
CIC Agreement would control. There would be no duplication of benefits provided under the Executive Severance Plan or otherwise. 
 Executive
Severance Plan 
 We expect that the Compensation Committee will approve an Executive Severance Plan in the near term. You will be eligible to
participate in the Executive Severance Plan. As President and CEO, in the event of your involuntary separation without Cause as defined under the plan, your severance benefit offer would include two times (2x) your final base salary; two times (2x)
your target annual bonus, and twenty-four (24) months of COBRA premiums (medical and dental) based on your coverage in effect immediately prior to your separation. All payments would be payable in a
lump-sum form, less applicable tax withholdings, subject to your entering into a general release in the form provided by the Company. There would be no duplication of benefits provided under the CIC Agreement
or otherwise. In the event the Company does not establish an Executive Severance Plan, the Company will provide you individual severance benefits, subject to the foregoing and other standard terms. 

U.S. Deferred Compensation Plan 
 As a valued
member of our Zimmer Biomet leadership team, you will be eligible to participate in the Zimmer Biomet Deferred Compensation Plan beginning January 1, 2018. 

The Deferred Compensation Plan offers: 
  

	 	•	 	Additional savings opportunities through voluntary deferrals and Company matching contributions; 

  

	 	•	 	Pre-tax earnings to help your account grow faster; and 

  

	 	•	 	In-service distribution options to help you plan for future events. 

Key features include: 
  

	 	•	 	The ability to defer up to 50% of your base salary and up to 95% of your annual bonus. 

  

	 	•	 	Matching contributions of 100% of your contribution up to a maximum of 6% of base salary and bonus, minus 401(k) matching contributions. 

Benefits 
 Zimmer Biomet provides a competitive
benefits program, with many of the benefits effective on your first day of active employment. Once you begin employment, you will receive an enrollment package from Zimmer Biomet Benefits Services, Zimmer Biomet’s group benefits

  

			
	

	  	Page 5

 

 
  

 
services administrator, regarding your medical, dental, and other group benefits. In addition, you will receive an enrollment package for our 401(k) plan, the Zimmer Biomet Holdings, Inc. Savings
and Investment Program, from Fidelity, our 401(k) services administrator. If you do not receive these mailings within two (2) weeks of your hire date, please contact Zimmer Biomet Benefit Services at 1-877-588-0933 or Fidelity at 1-800-835-5095.
You must enroll in the various medical plans within thirty-one (31) calendar days of your start date. 
 As
agreed and as an exception to Zimmer Biomet’s policy, you will accrue vacation at rate of four (4) weeks per calendar year, prorated in your year of hire, until you reach your tenth
(10th) year anniversary, after which you will be eligible for vacation in accordance with Zimmer Biomet’s standard vacation accrual policy. 

Relocation Assistance 
 Zimmer Biomet will assist
you with your relocation to the Warsaw/Fort Wayne/South Bend, Indiana area by paying for reasonable moving expenses incurred within one (1) year from the start of your employment in accordance with our Relocation Policy for similarly-situated
executives. Once you accept our offer of employment, you will be contacted directly by the relocation vendor to begin the relocation process. 

Personal Use of Company Aircraft 
 You will be
entitled to personal use of the Company’s aircraft up to a maximum incremental Company cost of two hundred thousand dollars ($200,000) per calendar year. You will be responsible for any tax liability arising from such aircraft usage, and the
value of this benefit will not be treated as compensation for purposes of any other bonus or benefit plan. 
 Conditions of Offer 

As a condition of and in consideration for employment with Zimmer Biomet, you must sign and return the enclosed
non-disclosure, intellectual property and restrictive covenant agreement. 
 Contractual Obligations

 We are aware of your Employee Agreement with your former employer that you signed on April 2, 2015. Should your former employer express an
intention or take action to prohibit or delay you from immediately serving as Zimmer Biomet’s President and CEO, we will engage in negotiations with your former employer and exert good faith reasonable efforts to resolve any such legal
challenge. For avoidance of doubt, we expect and trust that you will fully honor your confidentiality obligations to your former employer, as we are sure you intend to do. 

Section 409A 
 To the extent that any payments
or benefits under this letter are deemed to be subject to Section 409A of the Internal Revenue Code, this letter will be interpreted in accordance with Section 409A and Department of Treasury regulations and other interpretive guidance
issued thereunder in order to (a) preserve the intended tax treatment of the benefits provided with respect to such payments and (b) comply with the requirements of Section 409A. A termination of employment shall not be deemed to have
occurred for purposes of any provision of this letter providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of
Section 409A. Nothing in this letter shall be construed as a guarantee by the Company of any 

  

			
	

	  	Page 6

 

 
  

 
particular tax effect. The Company shall not be liable to you for any tax, penalty, or interest imposed on any amount paid or payable hereunder by reason of Section 409A, or for reporting in
good faith any payment made under this letter as an amount includible in gross income under Section 409A. 
 General Information and Additional
Enclosures 
 Zimmer Biomet is a federal contractor subject to Section 503 of the Rehabilitation Act of 1973 and as such, we are required to
extend to applicants post-offer invitations to identify themselves as individuals with disabilities or as disabled veterans, Vietnam-era veterans, or recently-separated veterans. Providing this information is
voluntary, and any information provided in response to this invitation will be kept confidential in accordance with the law. Failure or refusal to provide this information will not have an adverse effect on your employment. This information will be
used only for legal purposes. Invitations to self-identify are enclosed. 
 The Immigration Reform and Control Act of 1986 requires that employers verify
the legal status of all individuals beginning employment. This verification process is accomplished by reviewing certain types of documents to establish identity and legal authorization to work in the United States. Enclosed is Form I-9, which lists the documents you may provide for verification of employment eligibility and for proof of birth date. Please review this list and be prepared to provide the applicable original document(s) after you
accept this employment offer and no later than the third day of your employment. 
 Please note that all benefits are subject to the terms and conditions of
the applicable plan document or insurance policy, as amended from time to time. If there is any discrepancy between this letter and the plan documents, the plan documents will govern. While Zimmer Biomet intends to continue benefits referenced in
this offer, we reserve the right to change or discontinue them at any time for any reason. 
 Please note in particular that any amount payable or paid to
you pursuant to the Company EPIP or LTI Plan or any other similar performance-based compensation may be subject to forfeiture or repayment in accordance with the Company’s Executive Compensation Recoupment Policy or applicable plan document or
award agreement as approved, adopted and/or revised by the Board or Compensation Committee from time to time, and/or subject to recoupment as required by any other provisions of any law (including, without limitation, Section 10D of the
Securities Exchange Act of 1934, as amended), governmental regulation or stock exchange listing requirement. By signing below you acknowledge your understanding that any such repayment obligation will apply notwithstanding anything else stated in
this letter. 
 This letter does not create or constitute a contract of employment between you and Zimmer Biomet. Employment with Zimmer Biomet is “at
will,” which means that either you or Zimmer Biomet may terminate the employment relationship at any time for any reason, with or without cause or notice. 

We are very excited to have you join us and are looking forward to receiving your signed offer letter. We believe you will make a valuable contribution and
find your career with Zimmer Biomet challenging and rewarding. 

  

			
	

	  	Page 7

 

 
  

 CONFIRMATION OF ACCEPTANCE 

Please indicate your acceptance of this offer by signing below and returning the signed letter to me. At the same time, please also return your signed non-disclosure, intellectual property and restrictive covenant agreement. 
 This written offer voids and supersedes any
previous written or oral employment offers. 
 Sincerely, 
  

			
	 /s/ Bill P. Fisher
	  	
	Bill P. Fisher	  	
	Senior Vice President, Global Human Resources	  	

 I accept the position and the compensation elements outlined above, subject to the execution of the enclosed non-disclosure, intellectual property and restrictive covenant agreement. 
 Accepted: 

 

			
	 /s/ Bryan C. Hanson
	  	 December 18, 2017

	Bryan C. Hanson	  	Date

  

			
	

	  	Page 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]